The PE Ratio as of September 2024 (TTM) for Kymera Therapeutics, Inc. (KYMR) is -18.68

According to Kymera Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -18.68. This represents a change of 29.79% compared to the average of -14.39 of the last 4 quarters.

Kymera Therapeutics, Inc. (KYMR) Historical PE Ratio (quarterly & annually)

How has KYMR PE Ratio performed in the past?

The mean historical PE Ratio of Kymera Therapeutics, Inc. over the last ten years is -23.60. The current -18.68 PE Ratio has changed 7.81% with respect to the historical average. Over the past ten years (40 quarters), KYMR's PE Ratio was at its highest in in the September 2023 quarter at -3.84. The PE Ratio was at its lowest in in the December 2020 quarter at -54.34.

Kymera Therapeutics, Inc. (KYMR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Kymera Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kymera Therapeutics, Inc. (KYMR) Average PE Ratio

How has KYMR PE Ratio performed in the past?

The current PE Ratio of Kymera Therapeutics, Inc. (KYMR) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Kymera Therapeutics, Inc. (KYMR) PE Ratio vs. Peers

How is KYMR’s PE Ratio compared to its peers?

Kymera Therapeutics, Inc.’s PE Ratio is less than Foghorn Therapeutics Inc. (-4.49), less than Shattuck Labs, Inc. (-2.08), less than Monte Rosa Therapeutics, Inc. (-3.11), less than Nurix Therapeutics, Inc. (-8.82), less than Revolution Medicines, Inc. (-13.31), less than C4 Therapeutics, Inc. (-3.44), less than Agios Pharmaceuticals, Inc. (-6.74), less than Century Therapeutics, Inc. (-0.91), less than Edgewise Therapeutics, Inc. (-14.14), less than Mineralys Therapeutics, Inc. (-4.63), less than Cullinan Oncology, Inc. (-6.96), less than Eliem Therapeutics, Inc. (-3.49), less than Prelude Therapeutics Incorporated (-2.83),

Build a custom stock screener for Kymera Therapeutics, Inc. (KYMR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kymera Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kymera Therapeutics, Inc. (KYMR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kymera Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.